Press Release

ProJenX Announces First Person Dosed in Phase 1 Study of Prosetin

ProJenX launches to advance novel, targeted therapies for ALS and other brain diseases

Immunitas Therapeutics Names Amanda Wagner as CEO

Immunitas Therapeutics Appoints Seng-Lai ‘Thomas’ Tan, Ph.D. as Chief Scientific Officer

Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases